OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Neurology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
	176
Issue Information	109
Structural correlations between brain magnetic resonance image‐derived phenotypes and retinal neuroanatomy	105
Central nervous system crystal‐storing histiocytosis: A case report and literature review	99
Lessons from the past to understand the future	98
CCR5‐Δ32polymorphism—a possible protective factor from gait impairment amongst post‐stroke patients	94
Clusters of Comorbidities in Multiple Sclerosis and Their Influence on Healthcare Resource Usage	86
Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift	83
Out‐of‐hospital versus in‐hospital status epilepticus: The role of etiology and comorbidities	83
Concerns Regarding “Small Fiber Morphology and Function in Inclusion Body Myositis—A Multimodal Assessment Including Confocal Corneal Microscopy”	71
Cost‐effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health‐related quality of life	70
A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis	68
Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed	63
	63
Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study	60
Response to erenumab assessed by Headache Impact Test‐6 is modulated by genetic factors and arterial hypertension: An explorative cohort study	59
Clinical and Genetic Reassessment in Patients With Clinically Diagnosed Hereditary Polyneuropathy	56
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment	54
	54
Ischaemic cerebral small vessel disease caused by adenosine deaminase 2 deficiency syndrome	54
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease	54
ePoster	54
Altered grey matter integrity and network vulnerability relate to epilepsy occurrence in patients with multiple sclerosis	53
Electroencephalography functional connectivity—A biomarker for painful polyneuropathy	52
The 2022 European postgraduate (residency) programme in neurology in a historical and international perspective	51

Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report	50
Comparative features and outcomes of major neurological complications of COVID‐19	46
Hearing impairment and development of parkinsonism and possible rapid eye movement sleep behaviour disorder: A CLSA prospective population‐based study	46
Neuropathy in GAA‐FGF14 Late‐Onset Cerebellar Ataxia (SCA27B): Prevalence and Characteristics	45
The effect of influenza vaccination on the rate of dementia amongst older adults	45
The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications	45
Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review	45
Correlation between patient‐reported manual ability and three objective measures of upper limb function in people with multiple sclerosis	44
1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China	43
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study	43
Prevalence and Impact of Probable REM Sleep Behavior Disorder in Essential Tremor: A Multicenter Cross‐Sectional Study	43
Diagnostic accuracy of nerve excitability and compound muscle action potential scan derived biomarkers in amyotrophic lateral sclerosis	41
Basal ganglia ischaemic infarction after thrombectomy: cognitive impairment at acute stage	41
Prioritization process for European Academy of Neurology clinical practice guidelines	41
Mindfulness or meditation therapy for Parkinson's disease: A systematic review and meta‐analysis of randomized controlled trials	40
Issue Information	40
COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition	40